Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tania Kümpfel

Showing results (1-10 of 212) with videos related to

Pageof 22
Sort By:
MMW Fortschritte Der Medizin|July 3, 2016
[Not Available]Tania Kümpfel
Nature Reviews. Neurology|October 2, 2009
Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosisTania Kümpfel, Reinhard Hohlfeld
JAMA Neurology|April 5, 2016
Alemtuzumab and Multiple Sclerosis: Another Note of CautionReinhard Hohlfeld, Tania Kümpfel
Der Nervenarzt|March 17, 2021
[From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification]Orhan Aktas, Tania Kümpfel
Schmerz (Berlin, Germany)|May 25, 2021
[Pain in multiple sclerosis and neuromyelitis optica spectrum disorders]Hannah L Pellkofer, Tania Kümpfel
Current Opinion in Neurology|June 8, 2022
Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyondSimone Mader, Tania Kümpfel, Edgar Meinl
Therapeutics and Clinical Risk Management|October 15, 2013
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?Joachim Havla, Ingo Kleiter, Tania Kümpfel
Multiple Sclerosis and Related Disorders|April 17, 2015
Late-onset neutropenia during long-term rituximab therapy in neuromyelitis opticaAnnika Plate, Joachim Havla, Tania Kümpfel
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2017
Patient-to-patient transmission of natalizumab-associated PML?Reinhard Hohlfeld, Joachim Havla, Tania Kümpfel
Current Opinion in Neurology|April 19, 2020
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseasesSimone Mader, Tania Kümpfel, Edgar Meinl
Pageof 22

Showing results (1-10 of 212) with videos related to

Sort By:
Pageof 22
MMW Fortschritte Der Medizin|July 3, 2016
[Not Available]Tania Kümpfel
Nature Reviews. Neurology|October 2, 2009
Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosisTania Kümpfel, Reinhard Hohlfeld
JAMA Neurology|April 5, 2016
Alemtuzumab and Multiple Sclerosis: Another Note of CautionReinhard Hohlfeld, Tania Kümpfel
Der Nervenarzt|March 17, 2021
[From neuromyelitis optica to neuromyelitis optica spectrum disorder: from clinical syndrome to diagnistic classification]Orhan Aktas, Tania Kümpfel
Schmerz (Berlin, Germany)|May 25, 2021
[Pain in multiple sclerosis and neuromyelitis optica spectrum disorders]Hannah L Pellkofer, Tania Kümpfel
Current Opinion in Neurology|June 8, 2022
Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyondSimone Mader, Tania Kümpfel, Edgar Meinl
Therapeutics and Clinical Risk Management|October 15, 2013
Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?Joachim Havla, Ingo Kleiter, Tania Kümpfel
Multiple Sclerosis and Related Disorders|April 17, 2015
Late-onset neutropenia during long-term rituximab therapy in neuromyelitis opticaAnnika Plate, Joachim Havla, Tania Kümpfel
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 21, 2017
Patient-to-patient transmission of natalizumab-associated PML?Reinhard Hohlfeld, Joachim Havla, Tania Kümpfel
Current Opinion in Neurology|April 19, 2020
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseasesSimone Mader, Tania Kümpfel, Edgar Meinl
Pageof 22